Table 6:
Survival and time to disease progression in both treatment arms
|
Treatment outcome |
(Gem-Ox) (12 cases) |
(Gem-Ox-Pem) (16 cases) |
P Value |
|
|
Median time to progression (ms) |
6.1 (3.4-8.8) |
7.1 (2.7-11.5) |
0.58 |
|
|
Median survival, all cases (ms) |
11.3 (1.6-21) |
15.6 (6.8-24) |
0.34 |
|
|
Median survival (ms) |
||||
|
|
Stage
III-B |
12.6 (4.7-21) |
16.1 (8.1-24) |
0.08 |
|
Stage
IV |
7.1 (1.6-12.2) |
11.3 (6.8-14.9) |
0.09 |
|
|
One year-survival |
33.3% |
62.5% |
0.09 |
|
Gem, gemcitabine ; Ox,
oxaliplatin; Pem,
pemetrexed ; ms, months.